nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—TYMS—prostate cancer	0.413	1	CbGaD
Pralatrexate—TYMS—Capecitabine—prostate cancer	0.283	1	CbGbCtD
Pralatrexate—SLC19A1—prostate gland—prostate cancer	0.00639	0.146	CbGeAlD
Pralatrexate—FPGS—prostate gland—prostate cancer	0.00426	0.097	CbGeAlD
Pralatrexate—FPGS—seminal vesicle—prostate cancer	0.0036	0.082	CbGeAlD
Pralatrexate—FPGS—urethra—prostate cancer	0.00285	0.0649	CbGeAlD
Pralatrexate—SLC19A1—testis—prostate cancer	0.00282	0.0641	CbGeAlD
Pralatrexate—TYMS—prostate gland—prostate cancer	0.00279	0.0636	CbGeAlD
Pralatrexate—DHFR—prostate gland—prostate cancer	0.00277	0.063	CbGeAlD
Pralatrexate—DHFR—seminal vesicle—prostate cancer	0.00234	0.0533	CbGeAlD
Pralatrexate—SLC19A1—lymph node—prostate cancer	0.00204	0.0465	CbGeAlD
Pralatrexate—DHFR—renal system—prostate cancer	0.00188	0.0429	CbGeAlD
Pralatrexate—FPGS—testis—prostate cancer	0.00188	0.0427	CbGeAlD
Pralatrexate—DHFR—urethra—prostate cancer	0.00185	0.0422	CbGeAlD
Pralatrexate—TYMS—bone marrow—prostate cancer	0.00144	0.0328	CbGeAlD
Pralatrexate—DHFR—bone marrow—prostate cancer	0.00142	0.0324	CbGeAlD
Pralatrexate—FPGS—lymph node—prostate cancer	0.00136	0.031	CbGeAlD
Pralatrexate—TYMS—Docetaxel—Cabazitaxel—prostate cancer	0.00135	0.349	CbGdCrCtD
Pralatrexate—TYMS—testis—prostate cancer	0.00123	0.028	CbGeAlD
Pralatrexate—DHFR—testis—prostate cancer	0.00122	0.0277	CbGeAlD
Pralatrexate—Raltitrexed—TYMS—prostate cancer	0.000936	0.209	CrCbGaD
Pralatrexate—TYMS—Paclitaxel—Cabazitaxel—prostate cancer	0.000933	0.241	CbGdCrCtD
Pralatrexate—TYMS—lymph node—prostate cancer	0.000892	0.0203	CbGeAlD
Pralatrexate—DHFR—lymph node—prostate cancer	0.000883	0.0201	CbGeAlD
Pralatrexate—Methotrexate—AOX1—prostate cancer	0.000747	0.167	CrCbGaD
Pralatrexate—Leucovorin—TYMS—prostate cancer	0.00071	0.159	CrCbGaD
Pralatrexate—Pemetrexed—TYMS—prostate cancer	0.000567	0.127	CrCbGaD
Pralatrexate—TYMS—Paclitaxel—Docetaxel—prostate cancer	0.000387	0.1	CbGdCrCtD
Pralatrexate—Folic Acid—MTHFR—prostate cancer	0.000364	0.0814	CrCbGaD
Pralatrexate—Tetrahydrofolic acid—MTHFR—prostate cancer	0.000364	0.0814	CrCbGaD
Pralatrexate—Methotrexate—TYMS—prostate cancer	0.000313	0.07	CrCbGaD
Pralatrexate—TYMS—Podofilox—Etoposide—prostate cancer	0.000249	0.0642	CbGdCrCtD
Pralatrexate—Methotrexate—MTHFR—prostate cancer	0.000249	0.0557	CrCbGaD
Pralatrexate—TYMS—Levorphanol—Estrone—prostate cancer	0.000246	0.0636	CbGdCrCtD
Pralatrexate—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000241	0.00184	CcSEcCtD
Pralatrexate—Oedema—Conjugated Estrogens—prostate cancer	0.000241	0.00184	CcSEcCtD
Pralatrexate—Diarrhoea—Bicalutamide—prostate cancer	0.000239	0.00182	CcSEcCtD
Pralatrexate—Thrombocytopenia—Goserelin—prostate cancer	0.000238	0.00181	CcSEcCtD
Pralatrexate—Tachycardia—Goserelin—prostate cancer	0.000237	0.00181	CcSEcCtD
Pralatrexate—Tachycardia—Conjugated Estrogens—prostate cancer	0.000235	0.00179	CcSEcCtD
Pralatrexate—Dehydration—Docetaxel—prostate cancer	0.000235	0.00179	CcSEcCtD
Pralatrexate—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000233	0.00178	CcSEcCtD
Pralatrexate—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000233	0.00178	CcSEcCtD
Pralatrexate—Liver function test abnormal—Docetaxel—prostate cancer	0.000233	0.00178	CcSEcCtD
Pralatrexate—Anorexia—Goserelin—prostate cancer	0.000232	0.00177	CcSEcCtD
Pralatrexate—Anorexia—Conjugated Estrogens—prostate cancer	0.000229	0.00175	CcSEcCtD
Pralatrexate—Back pain—Estradiol—prostate cancer	0.000228	0.00174	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Docetaxel—prostate cancer	0.000227	0.00173	CcSEcCtD
Pralatrexate—Dehydration—Capecitabine—prostate cancer	0.000227	0.00173	CcSEcCtD
Pralatrexate—Liver function test abnormal—Capecitabine—prostate cancer	0.000226	0.00172	CcSEcCtD
Pralatrexate—Hypokalaemia—Capecitabine—prostate cancer	0.000222	0.0017	CcSEcCtD
Pralatrexate—Vomiting—Bicalutamide—prostate cancer	0.000222	0.00169	CcSEcCtD
Pralatrexate—Folic Acid—CYP2E1—prostate cancer	0.000221	0.0495	CrCbGaD
Pralatrexate—Rash—Bicalutamide—prostate cancer	0.00022	0.00168	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Capecitabine—prostate cancer	0.00022	0.00168	CcSEcCtD
Pralatrexate—Dermatitis—Bicalutamide—prostate cancer	0.00022	0.00168	CcSEcCtD
Pralatrexate—Dyspnoea—Goserelin—prostate cancer	0.000217	0.00165	CcSEcCtD
Pralatrexate—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000215	0.00164	CcSEcCtD
Pralatrexate—Back pain—Mitoxantrone—prostate cancer	0.000213	0.00162	CcSEcCtD
Pralatrexate—Asthenia—Ethinyl Estradiol—prostate cancer	0.000212	0.00162	CcSEcCtD
Pralatrexate—Decreased appetite—Goserelin—prostate cancer	0.000211	0.00161	CcSEcCtD
Pralatrexate—Fatigue—Goserelin—prostate cancer	0.000209	0.0016	CcSEcCtD
Pralatrexate—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000209	0.0016	CcSEcCtD
Pralatrexate—Pruritus—Ethinyl Estradiol—prostate cancer	0.000209	0.00159	CcSEcCtD
Pralatrexate—Constipation—Goserelin—prostate cancer	0.000208	0.00158	CcSEcCtD
Pralatrexate—Fatigue—Conjugated Estrogens—prostate cancer	0.000207	0.00158	CcSEcCtD
Pralatrexate—Nausea—Bicalutamide—prostate cancer	0.000207	0.00158	CcSEcCtD
Pralatrexate—Pancytopenia—Docetaxel—prostate cancer	0.000207	0.00158	CcSEcCtD
Pralatrexate—Cough—Estradiol—prostate cancer	0.000206	0.00157	CcSEcCtD
Pralatrexate—Constipation—Conjugated Estrogens—prostate cancer	0.000206	0.00157	CcSEcCtD
Pralatrexate—Neutropenia—Docetaxel—prostate cancer	0.000204	0.00156	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—prostate cancer	0.000203	0.00155	CcSEcCtD
Pralatrexate—Anaemia—Mitoxantrone—prostate cancer	0.000203	0.00155	CcSEcCtD
Pralatrexate—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000202	0.00154	CcSEcCtD
Pralatrexate—Pancytopenia—Capecitabine—prostate cancer	0.000201	0.00153	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Goserelin—prostate cancer	0.000199	0.00152	CcSEcCtD
Pralatrexate—Hypokalaemia—Prednisone—prostate cancer	0.000198	0.00151	CcSEcCtD
Pralatrexate—Neutropenia—Capecitabine—prostate cancer	0.000197	0.00151	CcSEcCtD
Pralatrexate—Leukopenia—Mitoxantrone—prostate cancer	0.000197	0.0015	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000197	0.0015	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000196	0.0015	CcSEcCtD
Pralatrexate—Oedema—Estradiol—prostate cancer	0.000193	0.00147	CcSEcCtD
Pralatrexate—Abdominal pain—Goserelin—prostate cancer	0.000192	0.00146	CcSEcCtD
Pralatrexate—Body temperature increased—Goserelin—prostate cancer	0.000192	0.00146	CcSEcCtD
Pralatrexate—Cough—Mitoxantrone—prostate cancer	0.000192	0.00146	CcSEcCtD
Pralatrexate—Abdominal pain—Conjugated Estrogens—prostate cancer	0.00019	0.00145	CcSEcCtD
Pralatrexate—Body temperature increased—Conjugated Estrogens—prostate cancer	0.00019	0.00145	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—prostate cancer	0.000188	0.00144	CcSEcCtD
Pralatrexate—Tachycardia—Estradiol—prostate cancer	0.000188	0.00143	CcSEcCtD
Pralatrexate—Vomiting—Ethinyl Estradiol—prostate cancer	0.000188	0.00143	CcSEcCtD
Pralatrexate—TYMS—Levorphanol—Estradiol—prostate cancer	0.000187	0.0482	CbGdCrCtD
Pralatrexate—Rash—Ethinyl Estradiol—prostate cancer	0.000186	0.00142	CcSEcCtD
Pralatrexate—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000186	0.00142	CcSEcCtD
Pralatrexate—Epistaxis—Docetaxel—prostate cancer	0.000183	0.0014	CcSEcCtD
Pralatrexate—Oedema—Mitoxantrone—prostate cancer	0.000179	0.00137	CcSEcCtD
Pralatrexate—Epistaxis—Capecitabine—prostate cancer	0.000178	0.00135	CcSEcCtD
Pralatrexate—Back pain—Etoposide—prostate cancer	0.000177	0.00135	CcSEcCtD
Pralatrexate—Neutropenia—Prednisone—prostate cancer	0.000176	0.00134	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000176	0.00134	CcSEcCtD
Pralatrexate—Nausea—Ethinyl Estradiol—prostate cancer	0.000175	0.00134	CcSEcCtD
Pralatrexate—Tachycardia—Mitoxantrone—prostate cancer	0.000175	0.00134	CcSEcCtD
Pralatrexate—Asthenia—Goserelin—prostate cancer	0.000174	0.00133	CcSEcCtD
Pralatrexate—Asthenia—Conjugated Estrogens—prostate cancer	0.000173	0.00132	CcSEcCtD
Pralatrexate—Pruritus—Goserelin—prostate cancer	0.000172	0.00131	CcSEcCtD
Pralatrexate—Dyspnoea—Estradiol—prostate cancer	0.000172	0.00131	CcSEcCtD
Pralatrexate—Anorexia—Mitoxantrone—prostate cancer	0.000171	0.0013	CcSEcCtD
Pralatrexate—Pruritus—Conjugated Estrogens—prostate cancer	0.00017	0.0013	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—prostate cancer	0.00017	0.0013	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—prostate cancer	0.000169	0.00129	CcSEcCtD
Pralatrexate—Decreased appetite—Estradiol—prostate cancer	0.000167	0.00128	CcSEcCtD
Pralatrexate—Diarrhoea—Goserelin—prostate cancer	0.000166	0.00127	CcSEcCtD
Pralatrexate—Fatigue—Estradiol—prostate cancer	0.000166	0.00127	CcSEcCtD
Pralatrexate—Constipation—Estradiol—prostate cancer	0.000165	0.00126	CcSEcCtD
Pralatrexate—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000165	0.00126	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—prostate cancer	0.000164	0.00125	CcSEcCtD
Pralatrexate—Dyspnoea—Mitoxantrone—prostate cancer	0.00016	0.00122	CcSEcCtD
Pralatrexate—Cough—Etoposide—prostate cancer	0.00016	0.00122	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—prostate cancer	0.000158	0.00121	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—prostate cancer	0.000157	0.0012	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Estradiol—prostate cancer	0.000157	0.0012	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—prostate cancer	0.000157	0.0012	CcSEcCtD
Pralatrexate—Decreased appetite—Mitoxantrone—prostate cancer	0.000156	0.00119	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—prostate cancer	0.000155	0.00118	CcSEcCtD
Pralatrexate—Fatigue—Mitoxantrone—prostate cancer	0.000155	0.00118	CcSEcCtD
Pralatrexate—Vomiting—Goserelin—prostate cancer	0.000154	0.00118	CcSEcCtD
Pralatrexate—Constipation—Mitoxantrone—prostate cancer	0.000153	0.00117	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000153	0.00117	CcSEcCtD
Pralatrexate—Rash—Goserelin—prostate cancer	0.000153	0.00117	CcSEcCtD
Pralatrexate—Dermatitis—Goserelin—prostate cancer	0.000153	0.00117	CcSEcCtD
Pralatrexate—Vomiting—Conjugated Estrogens—prostate cancer	0.000153	0.00117	CcSEcCtD
Pralatrexate—Abdominal pain—Estradiol—prostate cancer	0.000152	0.00116	CcSEcCtD
Pralatrexate—Body temperature increased—Estradiol—prostate cancer	0.000152	0.00116	CcSEcCtD
Pralatrexate—Rash—Conjugated Estrogens—prostate cancer	0.000152	0.00116	CcSEcCtD
Pralatrexate—Dermatitis—Conjugated Estrogens—prostate cancer	0.000152	0.00116	CcSEcCtD
Pralatrexate—Back pain—Docetaxel—prostate cancer	0.000147	0.00112	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000147	0.00112	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—prostate cancer	0.000146	0.00112	CcSEcCtD
Pralatrexate—Thrombocytopenia—Etoposide—prostate cancer	0.000146	0.00111	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—prostate cancer	0.000146	0.00111	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—prostate cancer	0.000145	0.00111	CcSEcCtD
Pralatrexate—Nausea—Goserelin—prostate cancer	0.000144	0.0011	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—prostate cancer	0.000143	0.00109	CcSEcCtD
Pralatrexate—Nausea—Conjugated Estrogens—prostate cancer	0.000143	0.00109	CcSEcCtD
Pralatrexate—Back pain—Capecitabine—prostate cancer	0.000142	0.00109	CcSEcCtD
Pralatrexate—Anorexia—Etoposide—prostate cancer	0.000142	0.00109	CcSEcCtD
Pralatrexate—Body temperature increased—Mitoxantrone—prostate cancer	0.000142	0.00108	CcSEcCtD
Pralatrexate—Abdominal pain—Mitoxantrone—prostate cancer	0.000142	0.00108	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000142	0.00108	CcSEcCtD
Pralatrexate—Anaemia—Docetaxel—prostate cancer	0.00014	0.00107	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—prostate cancer	0.00014	0.00107	CcSEcCtD
Pralatrexate—Asthenia—Estradiol—prostate cancer	0.000138	0.00105	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—prostate cancer	0.000138	0.00105	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000137	0.00104	CcSEcCtD
Pralatrexate—Pruritus—Estradiol—prostate cancer	0.000136	0.00104	CcSEcCtD
Pralatrexate—Leukopenia—Docetaxel—prostate cancer	0.000136	0.00104	CcSEcCtD
Pralatrexate—Anaemia—Capecitabine—prostate cancer	0.000136	0.00104	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—prostate cancer	0.000133	0.00101	CcSEcCtD
Pralatrexate—Cough—Docetaxel—prostate cancer	0.000133	0.00101	CcSEcCtD
Pralatrexate—Diarrhoea—Estradiol—prostate cancer	0.000132	0.001	CcSEcCtD
Pralatrexate—Leukopenia—Capecitabine—prostate cancer	0.000132	0.001	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—prostate cancer	0.00013	0.00099	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—prostate cancer	0.000129	0.000986	CcSEcCtD
Pralatrexate—Asthenia—Mitoxantrone—prostate cancer	0.000129	0.000982	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—prostate cancer	0.000129	0.000981	CcSEcCtD
Pralatrexate—Cough—Capecitabine—prostate cancer	0.000128	0.000979	CcSEcCtD
Pralatrexate—Constipation—Etoposide—prostate cancer	0.000128	0.000973	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—prostate cancer	0.000127	0.000971	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000127	0.000965	CcSEcCtD
Pralatrexate—Oedema—Docetaxel—prostate cancer	0.000124	0.000946	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—prostate cancer	0.000124	0.000944	CcSEcCtD
Pralatrexate—TYMS—Danazol—Ethinyl Estradiol—prostate cancer	0.000123	0.0318	CbGdCrCtD
Pralatrexate—Diarrhoea—Mitoxantrone—prostate cancer	0.000123	0.000936	CcSEcCtD
Pralatrexate—Vomiting—Estradiol—prostate cancer	0.000122	0.000934	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—prostate cancer	0.000122	0.000931	CcSEcCtD
Pralatrexate—Thrombocytopenia—Docetaxel—prostate cancer	0.000121	0.000926	CcSEcCtD
Pralatrexate—Rash—Estradiol—prostate cancer	0.000121	0.000926	CcSEcCtD
Pralatrexate—Dermatitis—Estradiol—prostate cancer	0.000121	0.000925	CcSEcCtD
Pralatrexate—Anaemia—Prednisone—prostate cancer	0.000121	0.000924	CcSEcCtD
Pralatrexate—Tachycardia—Docetaxel—prostate cancer	0.000121	0.000923	CcSEcCtD
Pralatrexate—Oedema—Capecitabine—prostate cancer	0.00012	0.000916	CcSEcCtD
Pralatrexate—Anorexia—Docetaxel—prostate cancer	0.000118	0.000902	CcSEcCtD
Pralatrexate—Body temperature increased—Etoposide—prostate cancer	0.000118	0.0009	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—prostate cancer	0.000118	0.0009	CcSEcCtD
Pralatrexate—Thrombocytopenia—Capecitabine—prostate cancer	0.000118	0.000897	CcSEcCtD
Pralatrexate—Tachycardia—Capecitabine—prostate cancer	0.000117	0.000894	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—prostate cancer	0.000114	0.000873	CcSEcCtD
Pralatrexate—Anorexia—Capecitabine—prostate cancer	0.000114	0.000873	CcSEcCtD
Pralatrexate—Nausea—Estradiol—prostate cancer	0.000114	0.000872	CcSEcCtD
Pralatrexate—Vomiting—Mitoxantrone—prostate cancer	0.000114	0.00087	CcSEcCtD
Pralatrexate—Rash—Mitoxantrone—prostate cancer	0.000113	0.000863	CcSEcCtD
Pralatrexate—Dermatitis—Mitoxantrone—prostate cancer	0.000113	0.000862	CcSEcCtD
Pralatrexate—Dyspnoea—Docetaxel—prostate cancer	0.000111	0.000843	CcSEcCtD
Pralatrexate—Decreased appetite—Docetaxel—prostate cancer	0.000108	0.000822	CcSEcCtD
Pralatrexate—Asthenia—Etoposide—prostate cancer	0.000107	0.000817	CcSEcCtD
Pralatrexate—Dyspnoea—Capecitabine—prostate cancer	0.000107	0.000817	CcSEcCtD
Pralatrexate—Oedema—Prednisone—prostate cancer	0.000107	0.000816	CcSEcCtD
Pralatrexate—Fatigue—Docetaxel—prostate cancer	0.000107	0.000816	CcSEcCtD
Pralatrexate—Nausea—Mitoxantrone—prostate cancer	0.000107	0.000813	CcSEcCtD
Pralatrexate—Constipation—Docetaxel—prostate cancer	0.000106	0.000809	CcSEcCtD
Pralatrexate—Pruritus—Etoposide—prostate cancer	0.000106	0.000805	CcSEcCtD
Pralatrexate—Tachycardia—Prednisone—prostate cancer	0.000104	0.000796	CcSEcCtD
Pralatrexate—Decreased appetite—Capecitabine—prostate cancer	0.000104	0.000796	CcSEcCtD
Pralatrexate—Fatigue—Capecitabine—prostate cancer	0.000104	0.00079	CcSEcCtD
Pralatrexate—Constipation—Capecitabine—prostate cancer	0.000103	0.000783	CcSEcCtD
Pralatrexate—Diarrhoea—Etoposide—prostate cancer	0.000102	0.000779	CcSEcCtD
Pralatrexate—Anorexia—Prednisone—prostate cancer	0.000102	0.000778	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Docetaxel—prostate cancer	0.000101	0.000774	CcSEcCtD
Pralatrexate—Back pain—Epirubicin—prostate cancer	9.92e-05	0.000756	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Capecitabine—prostate cancer	9.82e-05	0.000749	CcSEcCtD
Pralatrexate—Abdominal pain—Docetaxel—prostate cancer	9.8e-05	0.000748	CcSEcCtD
Pralatrexate—Body temperature increased—Docetaxel—prostate cancer	9.8e-05	0.000748	CcSEcCtD
Pralatrexate—Abdominal pain—Capecitabine—prostate cancer	9.49e-05	0.000724	CcSEcCtD
Pralatrexate—Body temperature increased—Capecitabine—prostate cancer	9.49e-05	0.000724	CcSEcCtD
Pralatrexate—Vomiting—Etoposide—prostate cancer	9.49e-05	0.000724	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—prostate cancer	9.47e-05	0.000723	CcSEcCtD
Pralatrexate—Rash—Etoposide—prostate cancer	9.41e-05	0.000718	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—prostate cancer	9.4e-05	0.000717	CcSEcCtD
Pralatrexate—Decreased appetite—Prednisone—prostate cancer	9.3e-05	0.000709	CcSEcCtD
Pralatrexate—Fatigue—Prednisone—prostate cancer	9.22e-05	0.000703	CcSEcCtD
Pralatrexate—Leukopenia—Epirubicin—prostate cancer	9.18e-05	0.0007	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—prostate cancer	9.17e-05	0.0007	CcSEcCtD
Pralatrexate—Constipation—Prednisone—prostate cancer	9.15e-05	0.000698	CcSEcCtD
Pralatrexate—Cough—Epirubicin—prostate cancer	8.94e-05	0.000682	CcSEcCtD
Pralatrexate—Asthenia—Docetaxel—prostate cancer	8.9e-05	0.000679	CcSEcCtD
Pralatrexate—Nausea—Etoposide—prostate cancer	8.86e-05	0.000676	CcSEcCtD
Pralatrexate—TYMS—Levonorgestrel—Ethinyl Estradiol—prostate cancer	8.84e-05	0.0228	CbGdCrCtD
Pralatrexate—Pruritus—Docetaxel—prostate cancer	8.77e-05	0.000669	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—prostate cancer	8.77e-05	0.000669	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Prednisone—prostate cancer	8.75e-05	0.000667	CcSEcCtD
Pralatrexate—Asthenia—Capecitabine—prostate cancer	8.62e-05	0.000657	CcSEcCtD
Pralatrexate—Pruritus—Capecitabine—prostate cancer	8.5e-05	0.000648	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—prostate cancer	8.49e-05	0.000648	CcSEcCtD
Pralatrexate—Diarrhoea—Docetaxel—prostate cancer	8.49e-05	0.000647	CcSEcCtD
Pralatrexate—Body temperature increased—Prednisone—prostate cancer	8.46e-05	0.000645	CcSEcCtD
Pralatrexate—Abdominal pain—Prednisone—prostate cancer	8.46e-05	0.000645	CcSEcCtD
Pralatrexate—Oedema—Epirubicin—prostate cancer	8.37e-05	0.000638	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—prostate cancer	8.28e-05	0.000631	CcSEcCtD
Pralatrexate—Diarrhoea—Capecitabine—prostate cancer	8.22e-05	0.000627	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—prostate cancer	8.19e-05	0.000625	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—prostate cancer	8.16e-05	0.000623	CcSEcCtD
Pralatrexate—Anorexia—Epirubicin—prostate cancer	7.97e-05	0.000608	CcSEcCtD
Pralatrexate—Vomiting—Docetaxel—prostate cancer	7.89e-05	0.000602	CcSEcCtD
Pralatrexate—Rash—Docetaxel—prostate cancer	7.82e-05	0.000597	CcSEcCtD
Pralatrexate—Dermatitis—Docetaxel—prostate cancer	7.81e-05	0.000596	CcSEcCtD
Pralatrexate—Oedema—Doxorubicin—prostate cancer	7.74e-05	0.00059	CcSEcCtD
Pralatrexate—Asthenia—Prednisone—prostate cancer	7.67e-05	0.000585	CcSEcCtD
Pralatrexate—Vomiting—Capecitabine—prostate cancer	7.64e-05	0.000582	CcSEcCtD
Pralatrexate—Thrombocytopenia—Doxorubicin—prostate cancer	7.58e-05	0.000578	CcSEcCtD
Pralatrexate—Rash—Capecitabine—prostate cancer	7.57e-05	0.000578	CcSEcCtD
Pralatrexate—Pruritus—Prednisone—prostate cancer	7.57e-05	0.000577	CcSEcCtD
Pralatrexate—Dermatitis—Capecitabine—prostate cancer	7.56e-05	0.000577	CcSEcCtD
Pralatrexate—Tachycardia—Doxorubicin—prostate cancer	7.55e-05	0.000576	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—prostate cancer	7.46e-05	0.000569	CcSEcCtD
Pralatrexate—Anorexia—Doxorubicin—prostate cancer	7.38e-05	0.000563	CcSEcCtD
Pralatrexate—Nausea—Docetaxel—prostate cancer	7.37e-05	0.000562	CcSEcCtD
Pralatrexate—Diarrhoea—Prednisone—prostate cancer	7.32e-05	0.000558	CcSEcCtD
Pralatrexate—Decreased appetite—Epirubicin—prostate cancer	7.27e-05	0.000555	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—prostate cancer	7.21e-05	0.00055	CcSEcCtD
Pralatrexate—Constipation—Epirubicin—prostate cancer	7.15e-05	0.000546	CcSEcCtD
Pralatrexate—Nausea—Capecitabine—prostate cancer	7.13e-05	0.000544	CcSEcCtD
Pralatrexate—Dyspnoea—Doxorubicin—prostate cancer	6.9e-05	0.000526	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Epirubicin—prostate cancer	6.84e-05	0.000522	CcSEcCtD
Pralatrexate—Vomiting—Prednisone—prostate cancer	6.8e-05	0.000519	CcSEcCtD
Pralatrexate—Rash—Prednisone—prostate cancer	6.74e-05	0.000514	CcSEcCtD
Pralatrexate—Dermatitis—Prednisone—prostate cancer	6.74e-05	0.000514	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—prostate cancer	6.73e-05	0.000513	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—prostate cancer	6.67e-05	0.000509	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—prostate cancer	6.62e-05	0.000505	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—prostate cancer	6.61e-05	0.000504	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—prostate cancer	6.61e-05	0.000504	CcSEcCtD
Pralatrexate—Nausea—Prednisone—prostate cancer	6.35e-05	0.000485	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Doxorubicin—prostate cancer	6.33e-05	0.000483	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—prostate cancer	6.12e-05	0.000467	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—prostate cancer	6.12e-05	0.000467	CcSEcCtD
Pralatrexate—Asthenia—Epirubicin—prostate cancer	6e-05	0.000458	CcSEcCtD
Pralatrexate—Pruritus—Epirubicin—prostate cancer	5.92e-05	0.000451	CcSEcCtD
Pralatrexate—TYMS—Clobetasol propionate—Prednisone—prostate cancer	5.73e-05	0.0148	CbGdCrCtD
Pralatrexate—Diarrhoea—Epirubicin—prostate cancer	5.72e-05	0.000437	CcSEcCtD
Pralatrexate—TYMS—Flunisolide—Prednisone—prostate cancer	5.65e-05	0.0146	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Prednisone—prostate cancer	5.6e-05	0.0144	CbGdCrCtD
Pralatrexate—Asthenia—Doxorubicin—prostate cancer	5.55e-05	0.000424	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—prostate cancer	5.48e-05	0.000418	CcSEcCtD
Pralatrexate—Vomiting—Epirubicin—prostate cancer	5.32e-05	0.000406	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—prostate cancer	5.3e-05	0.000404	CcSEcCtD
Pralatrexate—Rash—Epirubicin—prostate cancer	5.27e-05	0.000402	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—prostate cancer	5.27e-05	0.000402	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Prednisone—prostate cancer	5.16e-05	0.0133	CbGdCrCtD
Pralatrexate—Nausea—Epirubicin—prostate cancer	4.97e-05	0.000379	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—prostate cancer	4.92e-05	0.000375	CcSEcCtD
Pralatrexate—Rash—Doxorubicin—prostate cancer	4.88e-05	0.000372	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—prostate cancer	4.88e-05	0.000372	CcSEcCtD
Pralatrexate—Nausea—Doxorubicin—prostate cancer	4.6e-05	0.000351	CcSEcCtD
Pralatrexate—TYMS—Budesonide—Prednisone—prostate cancer	4.52e-05	0.0117	CbGdCrCtD
Pralatrexate—TYMS—Danazol—Prednisone—prostate cancer	4.33e-05	0.0112	CbGdCrCtD
Pralatrexate—FPGS—Disease—MAP2K1—prostate cancer	2.75e-05	0.000229	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	2.74e-05	0.000228	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CD—prostate cancer	2.73e-05	0.000227	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTA2—prostate cancer	2.71e-05	0.000225	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC22A1—prostate cancer	2.71e-05	0.000225	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SERPINE1—prostate cancer	2.7e-05	0.000225	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—ATM—prostate cancer	2.7e-05	0.000224	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CD—prostate cancer	2.69e-05	0.000224	CbGpPWpGaD
Pralatrexate—DHFR—Disease—B2M—prostate cancer	2.68e-05	0.000223	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFBR1—prostate cancer	2.68e-05	0.000223	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCG5—prostate cancer	2.68e-05	0.000223	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SULT1A1—prostate cancer	2.68e-05	0.000223	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SULT2A1—prostate cancer	2.64e-05	0.00022	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKR1C3—prostate cancer	2.64e-05	0.000219	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RPS19—prostate cancer	2.64e-05	0.000219	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1B—prostate cancer	2.63e-05	0.000218	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PRKACB—prostate cancer	2.62e-05	0.000218	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TERT—prostate cancer	2.62e-05	0.000218	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTA1—prostate cancer	2.62e-05	0.000217	CbGpPWpGaD
Pralatrexate—FPGS—Disease—FGF2—prostate cancer	2.62e-05	0.000217	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CG—prostate cancer	2.6e-05	0.000216	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—MED12—prostate cancer	2.6e-05	0.000216	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	2.59e-05	0.000216	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NAT2—prostate cancer	2.59e-05	0.000215	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HSD3B2—prostate cancer	2.59e-05	0.000215	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTO1—prostate cancer	2.59e-05	0.000215	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NOS3—prostate cancer	2.58e-05	0.000214	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GNG5—prostate cancer	2.58e-05	0.000214	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PPP3CA—prostate cancer	2.56e-05	0.000213	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NOS3—prostate cancer	2.54e-05	0.000211	CbGpPWpGaD
Pralatrexate—FPGS—Disease—JAK2—prostate cancer	2.51e-05	0.000208	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NCOA3—prostate cancer	2.48e-05	0.000207	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—prostate cancer	2.48e-05	0.000206	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLCB2—prostate cancer	2.48e-05	0.000206	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2C18—prostate cancer	2.48e-05	0.000206	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—LRP2—prostate cancer	2.48e-05	0.000206	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PRKCZ—prostate cancer	2.48e-05	0.000206	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—INS—prostate cancer	2.46e-05	0.000205	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MDM2—prostate cancer	2.45e-05	0.000203	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CALR—prostate cancer	2.43e-05	0.000202	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—P4HB—prostate cancer	2.43e-05	0.000202	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1A—prostate cancer	2.42e-05	0.000202	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—prostate cancer	2.42e-05	0.000201	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CREBBP—prostate cancer	2.41e-05	0.000201	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—prostate cancer	2.41e-05	0.000201	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PARP1—prostate cancer	2.39e-05	0.000199	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGFR4—prostate cancer	2.39e-05	0.000199	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	2.38e-05	0.000198	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CB—prostate cancer	2.38e-05	0.000198	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—HPGDS—prostate cancer	2.37e-05	0.000197	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC22A1—prostate cancer	2.37e-05	0.000197	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CALCA—prostate cancer	2.36e-05	0.000196	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—prostate cancer	2.36e-05	0.000196	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—ATM—prostate cancer	2.36e-05	0.000196	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2C19—prostate cancer	2.35e-05	0.000196	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CB—prostate cancer	2.34e-05	0.000195	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—prostate cancer	2.32e-05	0.000193	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EP300—prostate cancer	2.31e-05	0.000192	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SULT2A1—prostate cancer	2.31e-05	0.000192	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	2.3e-05	0.000192	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTT1—prostate cancer	2.3e-05	0.000191	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ACHE—prostate cancer	2.3e-05	0.000191	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CD—prostate cancer	2.29e-05	0.00019	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2A6—prostate cancer	2.27e-05	0.000189	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—MED12—prostate cancer	2.27e-05	0.000189	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HSPA1A—prostate cancer	2.26e-05	0.000188	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GNG5—prostate cancer	2.25e-05	0.000187	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SRC—prostate cancer	2.24e-05	0.000187	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1B—prostate cancer	2.23e-05	0.000186	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—prostate cancer	2.21e-05	0.000184	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKR1C3—prostate cancer	2.21e-05	0.000184	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PRKACB—prostate cancer	2.2e-05	0.000183	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP17A1—prostate cancer	2.18e-05	0.000181	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CASP9—prostate cancer	2.17e-05	0.000181	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NCOA3—prostate cancer	2.17e-05	0.00018	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—prostate cancer	2.16e-05	0.00018	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NOS3—prostate cancer	2.16e-05	0.00018	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—prostate cancer	2.11e-05	0.000175	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PRKCQ—prostate cancer	2.1e-05	0.000175	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NCOA2—prostate cancer	2.07e-05	0.000172	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HPGDS—prostate cancer	2.07e-05	0.000172	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1A—prostate cancer	2.06e-05	0.000171	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—prostate cancer	2.06e-05	0.000171	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2C19—prostate cancer	2.05e-05	0.000171	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—prostate cancer	2.03e-05	0.000169	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—prostate cancer	2.03e-05	0.000168	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—IL6—prostate cancer	2.03e-05	0.000168	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—prostate cancer	2.01e-05	0.000167	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TGFB1—prostate cancer	2.01e-05	0.000167	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ACHE—prostate cancer	2.01e-05	0.000167	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTT1—prostate cancer	2.01e-05	0.000167	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGF10—prostate cancer	2e-05	0.000166	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CB—prostate cancer	1.99e-05	0.000166	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MDM2—prostate cancer	1.99e-05	0.000166	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2A6—prostate cancer	1.98e-05	0.000165	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC5A5—prostate cancer	1.98e-05	0.000164	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—prostate cancer	1.98e-05	0.000164	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—prostate cancer	1.97e-05	0.000164	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EP300—prostate cancer	1.96e-05	0.000163	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.95e-05	0.000162	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—prostate cancer	1.94e-05	0.000161	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—EP300—prostate cancer	1.93e-05	0.000161	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2E1—prostate cancer	1.93e-05	0.000161	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKR1C3—prostate cancer	1.93e-05	0.00016	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PRKACB—prostate cancer	1.92e-05	0.000159	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NQO1—prostate cancer	1.91e-05	0.000159	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SRC—prostate cancer	1.91e-05	0.000159	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFBR2—prostate cancer	1.9e-05	0.000158	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP17A1—prostate cancer	1.9e-05	0.000158	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TH—prostate cancer	1.88e-05	0.000156	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—prostate cancer	1.88e-05	0.000156	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ITPR1—prostate cancer	1.87e-05	0.000156	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP3A4—prostate cancer	1.86e-05	0.000155	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—prostate cancer	1.86e-05	0.000154	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—prostate cancer	1.84e-05	0.000153	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP1B1—prostate cancer	1.83e-05	0.000152	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1B—prostate cancer	1.82e-05	0.000151	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NCOA2—prostate cancer	1.81e-05	0.00015	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—EP300—prostate cancer	1.79e-05	0.000149	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1B—prostate cancer	1.78e-05	0.000148	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GGT1—prostate cancer	1.77e-05	0.000147	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NCOA1—prostate cancer	1.75e-05	0.000145	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MDM2—prostate cancer	1.74e-05	0.000145	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—prostate cancer	1.74e-05	0.000144	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC5A5—prostate cancer	1.73e-05	0.000143	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—prostate cancer	1.72e-05	0.000143	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP19A1—prostate cancer	1.72e-05	0.000143	CbGpPWpGaD
Pralatrexate—DHFR—Disease—LPL—prostate cancer	1.72e-05	0.000143	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—prostate cancer	1.71e-05	0.000142	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—prostate cancer	1.71e-05	0.000142	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TGFB1—prostate cancer	1.71e-05	0.000142	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PDGFRB—prostate cancer	1.7e-05	0.000141	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—prostate cancer	1.69e-05	0.000141	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2E1—prostate cancer	1.69e-05	0.00014	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1A—prostate cancer	1.68e-05	0.00014	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—prostate cancer	1.67e-05	0.000139	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NQO1—prostate cancer	1.67e-05	0.000139	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—RXRA—prostate cancer	1.66e-05	0.000138	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERCC2—prostate cancer	1.64e-05	0.000137	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—EP300—prostate cancer	1.64e-05	0.000137	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TH—prostate cancer	1.64e-05	0.000137	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1A—prostate cancer	1.64e-05	0.000136	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP3A4—prostate cancer	1.63e-05	0.000135	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB3—prostate cancer	1.61e-05	0.000134	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGFR2—prostate cancer	1.6e-05	0.000133	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—COMT—prostate cancer	1.6e-05	0.000133	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP1B1—prostate cancer	1.6e-05	0.000133	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—EP300—prostate cancer	1.6e-05	0.000133	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTP1—prostate cancer	1.59e-05	0.000132	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1B—prostate cancer	1.59e-05	0.000132	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—prostate cancer	1.58e-05	0.000131	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ITPR1—prostate cancer	1.57e-05	0.00013	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—EP300—prostate cancer	1.56e-05	0.00013	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—prostate cancer	1.56e-05	0.000129	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GGT1—prostate cancer	1.55e-05	0.000129	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MTHFR—prostate cancer	1.54e-05	0.000128	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TERT—prostate cancer	1.54e-05	0.000128	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NCOA1—prostate cancer	1.52e-05	0.000127	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—prostate cancer	1.51e-05	0.000126	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6—prostate cancer	1.51e-05	0.000126	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP19A1—prostate cancer	1.5e-05	0.000125	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMS—prostate cancer	1.48e-05	0.000123	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HIF1A—prostate cancer	1.47e-05	0.000122	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1A—prostate cancer	1.47e-05	0.000122	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTM1—prostate cancer	1.46e-05	0.000122	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—prostate cancer	1.45e-05	0.000121	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—RXRA—prostate cancer	1.45e-05	0.000121	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—LPL—prostate cancer	1.44e-05	0.000119	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—prostate cancer	1.43e-05	0.000119	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CAV1—prostate cancer	1.42e-05	0.000118	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—COMT—prostate cancer	1.4e-05	0.000116	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—prostate cancer	1.39e-05	0.000116	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—EP300—prostate cancer	1.39e-05	0.000116	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—prostate cancer	1.39e-05	0.000116	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTP1—prostate cancer	1.39e-05	0.000116	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP1A1—prostate cancer	1.39e-05	0.000115	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ERCC2—prostate cancer	1.38e-05	0.000114	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ITPR1—prostate cancer	1.37e-05	0.000114	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—prostate cancer	1.36e-05	0.000113	CbGpPWpGaD
Pralatrexate—DHFR—Disease—BAD—prostate cancer	1.34e-05	0.000111	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APC—prostate cancer	1.3e-05	0.000108	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—MTHFR—prostate cancer	1.29e-05	0.000108	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6—prostate cancer	1.29e-05	0.000107	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGF—prostate cancer	1.28e-05	0.000107	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IRS1—prostate cancer	1.28e-05	0.000107	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTM1—prostate cancer	1.28e-05	0.000106	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPARA—prostate cancer	1.27e-05	0.000106	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—LPL—prostate cancer	1.25e-05	0.000104	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GSK3B—prostate cancer	1.25e-05	0.000104	CbGpPWpGaD
Pralatrexate—DHFR—Disease—INS—prostate cancer	1.23e-05	0.000102	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—prostate cancer	1.22e-05	0.000101	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—prostate cancer	1.21e-05	0.000101	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP1A1—prostate cancer	1.21e-05	0.000101	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CREBBP—prostate cancer	1.2e-05	0.0001	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ERCC2—prostate cancer	1.2e-05	9.98e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CAV1—prostate cancer	1.19e-05	9.92e-05	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—prostate cancer	1.19e-05	9.86e-05	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—prostate cancer	1.17e-05	9.71e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAP2K1—prostate cancer	1.15e-05	9.55e-05	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—prostate cancer	1.14e-05	9.51e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CD—prostate cancer	1.14e-05	9.49e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—MTHFR—prostate cancer	1.13e-05	9.39e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SERPINE1—prostate cancer	1.13e-05	9.38e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPARA—prostate cancer	1.11e-05	9.21e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGF2—prostate cancer	1.09e-05	9.08e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CG—prostate cancer	1.09e-05	9.04e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOS3—prostate cancer	1.08e-05	8.96e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—JAK2—prostate cancer	1.05e-05	8.71e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CAV1—prostate cancer	1.04e-05	8.66e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—INS—prostate cancer	1.03e-05	8.55e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MDM2—prostate cancer	1.02e-05	8.5e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CREBBP—prostate cancer	1.01e-05	8.38e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—prostate cancer	1.01e-05	8.38e-05	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—prostate cancer	9.98e-06	8.29e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CB—prostate cancer	9.95e-06	8.27e-05	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—prostate cancer	9.93e-06	8.26e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—prostate cancer	9.85e-06	8.19e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CD—prostate cancer	9.56e-06	7.94e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CG—prostate cancer	9.48e-06	7.89e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1B—prostate cancer	9.33e-06	7.76e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NOS3—prostate cancer	9.02e-06	7.5e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—INS—prostate cancer	8.98e-06	7.46e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—prostate cancer	8.82e-06	7.33e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CREBBP—prostate cancer	8.79e-06	7.31e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1A—prostate cancer	8.61e-06	7.16e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—prostate cancer	8.59e-06	7.14e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CD—prostate cancer	8.34e-06	6.93e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CB—prostate cancer	8.33e-06	6.92e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—prostate cancer	8.25e-06	6.86e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EP300—prostate cancer	8.2e-06	6.81e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SRC—prostate cancer	7.97e-06	6.63e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NOS3—prostate cancer	7.87e-06	6.55e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—prostate cancer	7.69e-06	6.39e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CB—prostate cancer	7.27e-06	6.04e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—prostate cancer	7.2e-06	5.99e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—prostate cancer	7.2e-06	5.98e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—prostate cancer	7.14e-06	5.94e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFB1—prostate cancer	7.12e-06	5.92e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—prostate cancer	6.99e-06	5.81e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—EP300—prostate cancer	6.86e-06	5.71e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—prostate cancer	6.6e-06	5.49e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—prostate cancer	6.28e-06	5.22e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—prostate cancer	6.06e-06	5.04e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—EP300—prostate cancer	5.99e-06	4.98e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6—prostate cancer	5.37e-06	4.46e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—prostate cancer	5.08e-06	4.22e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—prostate cancer	4.95e-06	4.12e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—prostate cancer	4.43e-06	3.68e-05	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—prostate cancer	4.15e-06	3.45e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—prostate cancer	3.62e-06	3.01e-05	CbGpPWpGaD
